BamSEC and AlphaSense Join Forces
Learn More

aTyr Pharma Inc.

NASDAQ: ATYR    
Share price (12/20/24): $3.35    
Market cap (12/20/24): $281 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 13 pages Atyr Pharma, Inc. 2015 Stock Option and Incentive Plan
12/34/56
EX-10.1
from 10-Q 6 pages First Amendment to Lease Between San Diego Creekside, LLC and Atyr Pharma, Inc
12/34/56
EX-10.19
from 10-K 3 pages Atyr Pharma, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 8-K 14 pages Atyr Pharma, Inc. 2015 Stock Option and Incentive Plan
12/34/56
EX-10.1
from 8-K 94 pages Lease Creekside Labs San Diego Creekside, LLC, a Delaware Limited Liability Company, as Landlord, and Atyr Pharma, Inc., a Delaware Corporation, as Tenant
12/34/56
EX-10.4
from 10-Q 12 pages Atyr Pharma, Inc. Stock Option Grant Notice
12/34/56
EX-10.3
from 10-Q 23 pages Atyr Pharma, Inc. 2022 Inducement Plan Adopted by the Compensation Committee: March 21, 2022
12/34/56
EX-10.2
from 8-K 5 pages Atyr Pharma, Inc. 2015 Employee Stock Purchase Plan
12/34/56
EX-10.1
from 8-K 13 pages Atyr Pharma, Inc. 2015 Stock Option and Incentive Plan
12/34/56
EX-10.20
from 10-K 23 pages Atyr Pharma, Inc. Common Stock ($0.001 Par Value Per Share) Capital on Demand™ Sales Agreement
12/34/56
EX-10.1
from 8-K 13 pages Atyr Pharma, Inc. 2015 Stock Option and Incentive Plan
12/34/56
EX-10.19
from 10-K ~1 page First Amendment to Employment Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Amendment No. 2 to Common Stock Sales Agreement
12/34/56
EX-10.1
from 8-K 19 pages 2015 Stock Option and Incentive Plan
12/34/56
EX-10.21
from S-1/A 61 pages Collaboration and License Agreement
12/34/56
EX-10.1
from 8-K 36 pages Atyr Pharma, Inc. Common Stock Sales Agreement
12/34/56
EX-10.2
from 10-Q 4 pages Atyr Pharma Brave Science, Meaningful Medicines
12/34/56
EX-10.1
from 8-K 18 pages 2015 Stock Option and Incentive Plan
12/34/56
EX-10.1
from 8-K 11 pages Atyr Pharma, Inc. Securities Purchase Agreement
12/34/56
EX-10.23
from 10-K 20 pages October 15, 2018 Personal and Confidential David J. King, PH.D. 310 Cole Ranch Road Encinitas, Ca 92024 Re:transition and Resignation Agreement
12/34/56